Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase III drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abiraterone acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abiraterone acetate overview
Abiraterone acetate (DRGT-45) is under development for the treatment of metastatic castration-resistant prostate cancer and castrate-sensitive prostate cancer. It is administered orally. It acts by targeting CYP17. The drug candidate is developed based on Super-API technology.
Tavanta Therapeutics overview
Tavanta Therapeutics (Tavanta) is involved developing diverse pipeline of specialty drugs. It is headquartered in Media, Pennsylvania, the US.
For a complete picture of Abiraterone acetate’s drug-specific PTSR and LoA scores, buy the report here.